Treating GA With ANX007

Jeffrey S. Heier, MD

Show Description +

Jeffrey S. Heier, MD, presents topline data from the phase 2 ARCHER study of ANX007 (Annexon) for the treatment of GA; secondary endpoints demonstrated protection against vision loss.

Posted: 8/08/2023

Keywords:

retina-meeting-recap

•

Clinical Trials

•

Annexon

•

Geographic Atrophy (GA)

•

Vision Loss

Up Next

Name: Treating GA With ANX007
Uploaded: 2023-08-08T15:36:36+00:00
Description: Jeffrey S. Heier, MD, presents topline data from the phase 2 ARCHER study of ANX007 (Annexon) for the treatment of GA; secondary endpoints demonstrated protection against vision loss.

Introducing a TWO-ROP Algorithm

Nimesh A. Patel, MD

When Infectious Retinitis Leads to an RD

Sruthi Arepalli, MD

ILM Flap Versus ILM Peeling for FTMH

Ankoor R. Shah, MD, FASRS

Wet AMD Incidence with GA Therapy

Roger Goldberg, MD, MBA

Tracking Vitreous Opacities After PPV

Shawn C. Kavoussi, MD

Methotrexate Shows Promise for Preventing PVR

Christina J. Flaxel, MD

Codes for Concurrent GA and Wet AMD

Jong G. Park, MD

High-Dose Aflibercept: 48-Week Data

Diana V. Do, MD, FASRS

Defining Anti-VEGF Response in CI-DME

Sharon D. Solomon, MD

Faricimab in Underrepresented Patients With DME

Joseph M. Coney, MD, FASRS

A Closer Look at 8 mg Aflibercept

David R. Chow, MD, FRCS(C)

Biosimilars in the Real World

Carl C. Awh, MD, FASRS

An Update on Suprachoroidal RGX-314

David S. Boyer, MD

Back to All Videos

Treating GA With ANX007

Jeffrey S. Heier, MD

Jeffrey S. Heier, MD, presents topline data from the phase 2 ARCHER study of ANX007 (Annexon) for the treatment of GA; secondary endpoints demonstrated protection against vision loss.

Posted: 8/08/2023

Keywords:

retina-meeting-recap

•

Clinical Trials

•

Annexon

•

Geographic Atrophy (GA)

•

Vision Loss

Please log in to leave a comment.

Meeting Coverage:

American Society of Retina Specialists Annual Meeting

Treating GA With ANX007

Up Next

Treating GA With ANX007

More From ASRS: 2023 Coverage